Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 8

1.

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.

Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, Popovici-Muller J, Saunders JO, Salituro FG, Yan S, Murray S, Wei W, Gao Y, Dang L, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, de Botton S, Yen KE.

Science. 2013 May 3;340(6132):622-6. doi: 10.1126/science.1234769. Epub 2013 Apr 4.

2.

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.

Popovici-Muller J, Saunders JO, Salituro FG, Travins JM, Yan S, Zhao F, Gross S, Dang L, Yen KE, Yang H, Straley KS, Jin S, Kunii K, Fantin VR, Zhang S, Pan Q, Shi D, Biller SA, Su SM.

ACS Med Chem Lett. 2012 Sep 17;3(10):850-5. doi: 10.1021/ml300225h. eCollection 2012 Oct 11.

3.

Pharmacologic inhibition of ghrelin receptor signaling is insulin sparing and promotes insulin sensitivity.

Longo KA, Govek EK, Nolan A, McDonagh T, Charoenthongtrakul S, Giuliana DJ, Morgan K, Hixon J, Zhou C, Kelder B, Kopchick JJ, Saunders JO, Navia MA, Curtis R, DiStefano PS, Geddes BJ.

J Pharmacol Exp Ther. 2011 Oct;339(1):115-24. doi: 10.1124/jpet.111.183764. Epub 2011 Jul 20. Erratum in: J Pharmacol Exp Ther. 2012 Mar;340(3):810.

4.

Characterization of the insulin sensitivity of ghrelin receptor KO mice using glycemic clamps.

Qi Y, Longo KA, Giuliana DJ, Gagne S, McDonagh T, Govek E, Nolan A, Zou C, Morgan K, Hixon J, Saunders JO, Distefano PS, Geddes BJ.

BMC Physiol. 2011 Jan 6;11:1. doi: 10.1186/1472-6793-11-1.

5.

Novel thiol-based TACE inhibitors: rational design, synthesis, and SAR of thiol-containing aryl sulfonamides.

Govinda Rao B, Bandarage UK, Wang T, Come JH, Perola E, Wei Y, Tian SK, Saunders JO.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2250-3. Epub 2007 Jan 26.

PMID:
17289381
6.

Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.

Napper AD, Hixon J, McDonagh T, Keavey K, Pons JF, Barker J, Yau WT, Amouzegh P, Flegg A, Hamelin E, Thomas RJ, Kates M, Jones S, Navia MA, Saunders JO, DiStefano PS, Curtis R.

J Med Chem. 2005 Dec 15;48(25):8045-54. Erratum in: J Med Chem. 2007 Mar 8;50(5):1086.

PMID:
16335928
7.

Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro.

Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J, Harding MW.

Anticancer Drugs. 1997 Feb;8(2):125-40.

PMID:
9073309
8.

Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506.

Armistead DM, Badia MC, Deininger DD, Duffy JP, Saunders JO, Tung RD, Thomson JA, DeCenzo MT, Futer O, Livingston DJ, Murcko MA, Yamashita MM, Navia MA.

Acta Crystallogr D Biol Crystallogr. 1995 Jul 1;51(Pt 4):522-8.

PMID:
15299839
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk